Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4726914> ?p ?o }
Showing triples 1 to 54 of
54
with 100 triples per page.
- Q4726914 subject Q7211373.
- Q4726914 abstract "Alirocumab (trade name Praluent) is a biopharmaceutical drug approved by the FDA on July 24, 2015 as a second line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.".
- Q4726914 atcPrefix "none".
- Q4726914 casNumber "1245916-14-6".
- Q4726914 wikiPageExternalLink praluent.pdf.
- Q4726914 wikiPageExternalLink www.praluent.com.
- Q4726914 wikiPageWikiLink Q12252367.
- Q4726914 wikiPageWikiLink Q1230226.
- Q4726914 wikiPageWikiLink Q1418791.
- Q4726914 wikiPageWikiLink Q14872724.
- Q4726914 wikiPageWikiLink Q158205.
- Q4726914 wikiPageWikiLink Q179661.
- Q4726914 wikiPageWikiLink Q202301.
- Q4726914 wikiPageWikiLink Q2035485.
- Q4726914 wikiPageWikiLink Q204711.
- Q4726914 wikiPageWikiLink Q26513.
- Q4726914 wikiPageWikiLink Q269829.
- Q4726914 wikiPageWikiLink Q2711291.
- Q4726914 wikiPageWikiLink Q285697.
- Q4726914 wikiPageWikiLink Q28749.
- Q4726914 wikiPageWikiLink Q30612.
- Q4726914 wikiPageWikiLink Q33123.
- Q4726914 wikiPageWikiLink Q3359612.
- Q4726914 wikiPageWikiLink Q3776943.
- Q4726914 wikiPageWikiLink Q389735.
- Q4726914 wikiPageWikiLink Q422248.
- Q4726914 wikiPageWikiLink Q470517.
- Q4726914 wikiPageWikiLink Q4914632.
- Q4726914 wikiPageWikiLink Q56646.
- Q4726914 wikiPageWikiLink Q582728.
- Q4726914 wikiPageWikiLink Q6060674.
- Q4726914 wikiPageWikiLink Q618446.
- Q4726914 wikiPageWikiLink Q624375.
- Q4726914 wikiPageWikiLink Q679692.
- Q4726914 wikiPageWikiLink Q7180823.
- Q4726914 wikiPageWikiLink Q7211373.
- Q4726914 wikiPageWikiLink Q7308054.
- Q4726914 wikiPageWikiLink Q762713.
- Q4726914 wikiPageWikiLink Q768231.
- Q4726914 wikiPageWikiLink Q79448.
- Q4726914 wikiPageWikiLink Q824258.
- Q4726914 wikiPageWikiLink Q845523.
- Q4726914 wikiPageWikiLink Q904407.
- Q4726914 wikiPageWikiLink Q949267.
- Q4726914 wikiPageWikiLink Q954845.
- Q4726914 atcPrefix "none".
- Q4726914 casNumber "1245916".
- Q4726914 type ChemicalSubstance.
- Q4726914 type Drug.
- Q4726914 type ChemicalObject.
- Q4726914 type Thing.
- Q4726914 type Q8386.
- Q4726914 comment "Alirocumab (trade name Praluent) is a biopharmaceutical drug approved by the FDA on July 24, 2015 as a second line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval.".
- Q4726914 label "Alirocumab".